Australia has long been recognised as a global leader in tobacco control. It pioneered plain packaging, high tobacco taxes, advertising restrictions and comprehensive smoking reduction strategies, yet questions remain about how effective some of these measures have been in delivering the outcomes promised.
Its latest reforms, however, mark a significant turning point in nicotine policy.
From 24 July 2026, the Therapeutic Goods Administration (TGA) has effectively removed every lawful pathway through which Australian adults can access nicotine pouches. Personal importation has been prohibited, prescribing through the Special Access Scheme (SAS) and Authorised Prescriber pathways has ended, pharmacy compounding is no longer permitted, and no nicotine pouch has been approved on the Australian Register of Therapeutic Goods (ARTG). Retail sales were already prohibited. In practical terms, nicotine pouches have become an illicit product category unless and until an ARTG-approved product exists, a product that currently does not exist.
This is no longer simply a debate about nicotine pouches.
It is a broader question about whether modern nicotine regulation is being designed to reduce harm or simply prohibit products.
When Regulation Becomes Prohibition
The TGA describes nicotine pouches as unapproved therapeutic goods and cites several concerns, including inconsistent nicotine strengths, potential contaminants, misleading labelling, and products manufactured outside recognised quality standards. These concerns deserve careful consideration and robust regulatory oversight.
However, the government’s response has not been to establish a pathway through which manufacturers can demonstrate compliance with defined safety and quality requirements. Instead, it has eliminated every practical legal avenue through which adults might obtain nicotine pouches while simultaneously strengthening enforcement against their importation, advertising, and supply.
This distinction matters.
Regulation establishes rules under which products can be assessed, improved, authorised, and monitored. Prohibition removes the legal pathway altogether.
By closing retail access, medical access, personal importation, and pharmacy compounding without providing a realistic approval pathway, Australia has effectively chosen prohibition over regulation for this product category.
An Inconsistent Harm Reduction Framework
Perhaps the most striking feature of Australia’s approach is the inconsistency it creates within its broader nicotine policy.
Combustible cigarettes, the nicotine product responsible for the overwhelming burden of smoking-related disease, remain legally available through licensed retail outlets across the country.
By contrast, nicotine pouches, which do not involve combustion, now have virtually no lawful route to market.
Whether one supports or opposes nicotine pouches is not the central issue.
The more important policy question is why the product associated with the greatest health risks remains legally accessible while a non-combustible category is prevented from entering a regulated market under defined standards.
A risk-proportionate regulatory framework would normally seek to distinguish between products according to their characteristics, patterns of use, and available scientific evidence rather than applying more restrictive access to products simply because they are newer.
The TGA’s Concerns Point Toward Standards Not a Ban
Ironically, the concerns cited by the TGA provide a compelling case for stronger product standards rather than eliminating lawful access.
If regulators are concerned about excessive nicotine strengths, inaccurate labelling, contaminants, or inconsistent manufacturing quality, these issues can be addressed through regulation.
Governments can establish maximum nicotine limits, require laboratory testing for contaminants, mandate ingredient disclosure, introduce manufacturing quality standards, require child-resistant packaging, implement product traceability systems, and enforce accurate labelling requirements.
These are precisely the kinds of regulatory tools designed to improve product quality while protecting consumers.
Removing legal pathways does not eliminate these risks. It removes regulators’ ability to distinguish compliant products from non-compliant ones because compliant products are no longer permitted to enter the market.
Demand Does Not Simply Disappear
History consistently demonstrates that prohibition does not necessarily eliminate consumer demand.
When demand persists but lawful supply is removed, consumers often turn to informal markets, online sellers, or illicit distribution networks operating outside regulatory oversight.
Australia has already experienced significant growth in illicit nicotine markets, with authorities reporting increasing seizures of illicit nicotine products and concerns about organised criminal involvement in their supply. The AMA itself has expressed concerns about youth access through online channels and called for stronger enforcement against illegal sales.
Closing lawful pathways may therefore change where products are obtained rather than whether they are obtained.
The unintended consequence is that regulators lose visibility over product quality, manufacturing standards, ingredient disclosure, and supply chains while illicit operators face none of the compliance obligations imposed on legitimate manufacturers.
Strong Enforcement Cannot Replace a Regulatory Pathway
Effective enforcement remains essential.
Illegal imports, non-compliant retailers, youth sales, misleading advertising, and organised illicit supply should all be subject to robust regulatory action.
However, enforcement works best when regulators have a legal market to supervise.
Without a lawful pathway, enforcement increasingly focuses on suppressing supply rather than ensuring product quality and compliance.
Regulatory systems are generally strongest when they can both remove non-compliant products and provide a transparent route for compliant products to enter the market under clearly defined standards.
The current Australian framework places almost exclusive emphasis on enforcement while offering no practical pathway through which manufacturers can demonstrate compliance and obtain market authorisation.
A More Proportionate Alternative
Protecting public health does not require a choice between unrestricted commercial availability and outright prohibition.
A proportionate regulatory framework could address many of the concerns identified by Australian authorities while maintaining meaningful regulatory oversight.
Such a framework could include strict age verification, retailer licensing, maximum nicotine limits, mandatory toxicological testing, manufacturing quality requirements, ingredient disclosure, child-resistant packaging, health warnings, post-market surveillance, adverse event reporting, and restrictions on marketing that appeals to young people.
Products that fail to meet these standards should not reach consumers.
Products that satisfy clearly defined regulatory requirements, however, should have a transparent pathway for assessment and authorisation.
This approach strengthens consumer protection while giving regulators the tools needed to monitor compliance, remove unsafe products, and improve market standards over time.
Lessons for Global Policymakers
Australia’s decision will be closely watched by governments reviewing nicotine regulation across Europe, Asia, Latin America, and beyond.
Many countries are currently asking similar questions about nicotine pouches, synthetic nicotine, and other emerging smoke-free products.
The Australian experience highlights an important policy lesson.
When governments close every legal pathway for a product category without creating a credible route for assessment and authorisation, they may reduce regulatory oversight rather than strengthen it. Demand does not necessarily disappear, but the opportunity to influence product quality, manufacturing standards, and consumer protections becomes significantly more limited.
Future-ready regulation should therefore seek not only to prevent harm but also to govern markets effectively.
Looking Ahead
Australia’s latest reforms reflect a strong commitment to protecting public health. The objectives of reducing youth access, preventing unsafe products from reaching consumers, and strengthening regulatory oversight are legitimate and widely shared.
The question is whether prohibition is the most effective way to achieve those objectives.
For GINN, effective nicotine regulation should combine robust product standards, strong enforcement, rigorous scientific evaluation, transparent authorisation pathways, and meaningful protections for young people.
Closing every legal pathway for nicotine pouches while combustible cigarettes remain legally available creates a difficult inconsistency within Australia’s harm reduction framework. Rather than encouraging safer, regulated alternatives to meet high standards, the current approach risks leaving combustible cigarettes as the most accessible legal nicotine product while pushing demand for smoke-free alternatives into illicit markets beyond regulatory oversight.
As governments continue to modernise nicotine policy, success should not be measured simply by the number of products prohibited. It should be measured by whether regulation reduces harm, protects young people, improves product quality, strengthens consumer confidence, and gives regulators meaningful oversight of an evolving marketplace.
